openPR Logo
Press release

Global Rheumatoid Arthritis Drug Market To Surpass USD 25 Billion in 2017

07-08-2017 01:52 PM CET | Health & Medicine

Press release from: Kuick Resarch

Global Rheumatoid Arthritis Drug Market To Surpass USD 25

“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights:

* Classification and Molecular Mechanism of Rheumatoid Arthritis Drugs
* Synthetic DMARDs as Rheumatoid Arthritis Drug
* Biological Agents as Rheumatoid Arthritis Drug
* Global Market of Rheumatoid Arthritis Drug
* Global Tendencies in Use of Antirheumatics
* Global Rheumatoid Arthritis Drug Market Future Prospect

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Download Report: https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php

Report Table of Contents

Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis

Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers

Classification of Rheumatoid Arthritis Drugs
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs

Synthetic DMARDs as Rheumatoid Arthritis Drug
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)

Biological Agents as Rheumatoid Arthritis Drug
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 and Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell and B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)

Global Prevalence of Rheumatoid Arthritis
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia

Global Tendencies in Use of Antirheumatics
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription

Global Market of Rheumatoid Arthritis Drug
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 and 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)

Global Rheumatoid Arthritis Drug Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges

Global Rheumatoid Arthritis Drug Market Future Prospect

Competitive Landscape
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 JandJ
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Rheumatoid Arthritis Drug Market To Surpass USD 25 Billion in 2017 here

News-ID: 615047 • Views: 907

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Rheumatoid

Global Rheumatoid Arthritis Drugs Market | MarketResearchReports.biz
Latest industry research report on: Global Rheumatoid Arthritis Drugs Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts The Rheumatoid Arthritis Drugs Market has been comprehensively detailed in the report with special focus on a range of key elements such as market share, forecast and base figures, CAGR, driving factors, growth restraints, and business opportunities. Buyers of the report are expected to be informed about significant
Rheumatoid Arthritis Drugs Sales Market Report 2017
Reports And Markets Publish a New Market Research Report On –"Rheumatoid Arthritis Drugs Sales Market Report 2017" Access Full Report With Table Of Contents @ https://www.reportsandmarkets.com/reports/global-rheumatoid-arthritis-drugs-sales-market-report-2017-1541249 In this report, the global Rheumatoid Arthritis Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the
Global Rheumatoid Arthritis Drug Market Outlook 2022
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi and Otezla) have dominated the overall anti-rheumatics market with
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the